Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Oncology
•
Medical Oncology
What is your experience with in vitro chemosensitivity testing?
What instances have you used this to help guide chemotherapy selection?
Related Questions
What does bevacizumab contribute in metastatic cervical cancer when used in combination with a platinum doublet + pembrolizumab?
What are your top takeaways in Gyn Cancers from ASCO 2025?
What strategies do you find helpful in advanced care planning with patients/families who are very "miracle" centered?
In general, how do you manage patients with early-stage endometrioid endometrial cancer who have concomitant POLE and TP53 mutations?
Do you have concerns about the validity of the INTERLACE data, considering the long study recruitment period (10 years) and evolution of radiation techniques that have occurred during that time frame?
For a patient with locally current endometrial cancer whose disease had complete radiographic response to carboplatin, Taxol, and pembrolizumab, would you consider adding radiation therapy?
How have you incorporated ctDNA into the clinical management of patients with gynecologic cancers?
What is your approach to IV fluid management for the treatment of hypercalcemia of malignancy?
What systemic therapy would you choose in a patient with PTEN-deleted metastatic uterine PEComa who has progression of disease after 3 cycles of albumin-bound sirolimus?
Would you consider adding immunotherapy to adjuvant chemotherapy in a patient with incompletely staged, high-grade, MSI-H, POLE-mutated endometrioid carcinoma of the ovary with ultra-high tumor mutation burden on NGS?